This result is important because CDK4/6 inhibitors are approved to treat luminal breast cancers (Finn et al, 2016; Slamon et al, 2020), but responsiveness has not consistently associated with the abundance of CDK4 mRNA (Finn et al, 2020; Turner et al, 2019). Here, CDK4 is linked to breast carcinoma.